Renaissance Technologies LLC acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 537,519 shares of the biopharmaceutical company’s stock, valued at approximately $12,046,000. Renaissance Technologies LLC owned about 0.55% of Fate Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in FATE. Envestnet Asset Management Inc. grew its stake in Fate Therapeutics by 20.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,734 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 1,457 shares during the last quarter. Raymond James & Associates grew its stake in Fate Therapeutics by 42.6% during the 1st quarter. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical company’s stock worth $1,141,000 after buying an additional 8,790 shares during the last quarter. HighTower Advisors LLC grew its stake in Fate Therapeutics by 5.9% during the 1st quarter. HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical company’s stock worth $714,000 after buying an additional 1,016 shares during the last quarter. Private Advisor Group LLC grew its stake in Fate Therapeutics by 25.7% during the 1st quarter. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 1,938 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Fate Therapeutics by 17.1% in the first quarter. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 986 shares in the last quarter.
Insider Activity
In other news, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $5.24, for a total transaction of $240,552.68. Following the transaction, the chief executive officer now owns 385,639 shares of the company’s stock, valued at approximately $2,020,748.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $5.24, for a total transaction of $240,552.68. Following the transaction, the chief executive officer now owns 385,639 shares of the company’s stock, valued at approximately $2,020,748.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John Mendlein bought 36,631 shares of the firm’s stock in a transaction that occurred on Friday, January 13th. The shares were acquired at an average price of $5.43 per share, with a total value of $198,906.33. Following the purchase, the director now owns 282,770 shares in the company, valued at $1,535,441.10. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 75,708 shares of company stock valued at $396,710. Insiders own 17.34% of the company’s stock.
Wall Street Analyst Weigh In
Fate Therapeutics Price Performance
Shares of FATE stock opened at $6.11 on Monday. The firm has a market cap of $599.76 million, a P/E ratio of -2.10 and a beta of 1.53. The stock’s 50-day moving average is $6.77 and its two-hundred day moving average is $16.46. Fate Therapeutics, Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $43.12.
Fate Therapeutics (NASDAQ:FATE – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.28. The business had revenue of $44.36 million for the quarter, compared to analyst estimates of $18.41 million. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The firm’s revenue for the quarter was up 159.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.72) EPS. As a group, research analysts expect that Fate Therapeutics, Inc. will post -2.13 EPS for the current year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.
Read More
- Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
